Brigatinib in Patients With Alectinib-Refractory ALK-Positive NSCLC
W. Marston Linehan(Harvard University), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Ibiayi Dagogo‐Jack(Massachusetts General Hospital), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Angela Marie Taber(Providence College), Subba R. Digumarthy(Massachusetts General Hospital), Anna F. Farago(Massachusetts General Hospital), Jochen K. Lennerz(Addgene), Lorin A. Ferris(Massachusetts General Hospital), Ashish Saxena(Cornell University), Alice T. Shaw(Dana-Farber Cancer Institute), Justin F. Gainor(Harvard University), Viola W. Zhu(University of California, Irvine), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Smitha Menon(Medical College of Wisconsin), Anne M. Traynor(University of Wisconsin Carbone Cancer Center), Beow Y. Yeap(Harvard University), Adam J. Schoenfeld(Memorial Sloan Kettering Cancer Center)
Cited by 82
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k